Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzheng Quxie prescription + Yifei Sanjie prescription is a combined traditional Chinese medicine (TCM) formulation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine. It is being investigated for the treatment of cancer-related fatigue (CRF) in patients with non-small cell lung cancer (NSCLC) undergoing postoperative adjuvant chemotherapy. The Yifei Sanjie component, also known as Yiqi Chutan Tang, is a classical TCM formula composed of multiple herbal ingredients including Panax quinquefolius Radix (Xi yang shen), Ranunculi Ternati Radix (Mao zhao cao), Sarcandrae Herba (Zhong jie feng), Pinelliae Rhizoma Praeparatum (Fa ban xia), Ganoderma (Ling zhi), Bombyx batryticatus (Chao jiang can), Cremastrae Pseudobulbus Pleiones Pseudobulbus (Shan ci gu), and Fritillariae Thunbergii Bulbus (Zhe bei mu). The proposed mechanism of action involves reducing skeletal muscle injury, inhibiting mitophagy and mitochondrial damage, and reducing oxidative stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fuzheng quxie prescription + yifei sanjie prescription.